Which combination of symptoms would most indicate potential cardiotoxicity in a patient receiving doxorubicin?

Which combination of symptoms would most indicate potential cardiotoxicity in a patient receiving doxorubicin?

• A. Fatigue alone
• B. Shortness of breath alone
• C. Fatigue, shortness of breath, and swelling
• D. Normal energy and no symptoms

Answer: (C)

Doxorubicin can cause dose-related damage to the heart muscle, leading to congestive heart failure. When this cardiotoxic effect is present, the heart’s ability to pump effectively declines, causing reduced output and fluid buildup. The combination of fatigue, shortness of breath, and swelling reflects this pattern: fatigue from lower perfusion, shortness of breath from pulmonary congestion, and swelling from systemic fluid retention. Seeing these together strongly points to cardiotoxicity rather than a single nonspecific symptom. Fatigue alone could be due to many things (anemia, infection, deconditioning), and shortness of breath alone might arise from lung or other issues. Normal energy and no symptoms obviously don’t indicate cardiac injury. In clinical practice, recognizing this symptom cluster prompts evaluation with cardiac imaging (such as echocardiography to assess ejection fraction) and appropriate management, including stopping the offending agent if cardiotoxicity is suspected and involving cardiology for further care.

Doxorubicin can cause dose-related damage to the heart muscle, leading to congestive heart failure. When this cardiotoxic effect is present, the heart’s ability to pump effectively declines, causing reduced output and fluid buildup. The combination of fatigue, shortness of breath, and swelling reflects this pattern: fatigue from lower perfusion, shortness of breath from pulmonary congestion, and swelling from systemic fluid retention. Seeing these together strongly points to cardiotoxicity rather than a single nonspecific symptom.

Fatigue alone could be due to many things (anemia, infection, deconditioning), and shortness of breath alone might arise from lung or other issues. Normal energy and no symptoms obviously don’t indicate cardiac injury. In clinical practice, recognizing this symptom cluster prompts evaluation with cardiac imaging (such as echocardiography to assess ejection fraction) and appropriate management, including stopping the offending agent if cardiotoxicity is suspected and involving cardiology for further care.